1例三联治疗难治性子宫内膜癌多发肺转移病案报道及文献复习
The Triple-Combination Therapy of Refractory Metastatic Endometrial Carcinoma: A Case Report and Literature Review
DOI: 10.12677/ACM.2023.1371585, PDF,    国家自然科学基金支持
作者: 刘 昕：西安医学院研究生院，陕西 西安；王天昶, 王锋刚, 刘秋芳*：陕西省肿瘤医院放疗病院，陕西 西安；穆允凤：陕西省肿瘤医院妇瘤病院，陕西 西安；刘 鹏：西安交通大学第一附属医院，MED-X再生与重建研究所，陕西 西安
关键词: 立体定向放射治疗；替雷利珠单抗；子宫内膜癌；肺转移；Stereotactic Ablative Radiotherapy； Tislelizumab； Endometrial Carcinoma； Lung Metastasis
摘要: 目的：晚期子宫内膜癌一线治疗的疗效普遍较低，目前尚无标准的二线治疗方案。本研究旨在探讨化疗失败后的子宫内膜癌多发肺转移患者应用三联疗法的临床意义及抗肿瘤机制。方法：给予患者立体定向消融放疗、粒细胞–巨噬细胞集落刺激因子(granulocyte-macrophage colony stimulating factor, GM- CSF)联合替雷利珠单抗的三联治疗。一共11个肺转移灶中的8个同时接受了50 Gy的SABR治疗。结果：治疗结束后6个月疗效评价为部分缓解。24个月后疗效评定为病情稳定。无进展生存期达24个月。本病例疗效显著，是首次将三联疗法应用在子宫内膜癌的病例报道。结论：基于这一病例，我们认为三联疗法是治疗子宫内膜癌肺转移患者的一种非常有潜力的二线治疗方法，值得进一步探索。
Abstract: Purpose: The therapeutic efficacy of first-line treatment for advanced endometrial carcinoma (EC) is generally reported to be low, and currently, there are no standard second-line treatment options. In this study, we aimed to explore the clinical significance and antitumor mechanism of tri-ple-combination therapy administered to a patient with chemotherapy-resistant, multiple lung metastases EC. Methods: The patient had 11 pulmonary metastatic lesions and underwent a triple- combination therapy with stereotactic ablative radiotherapy (SABR), granulocyte-macrophage col-ony-stimulating factor, and tislelizumab. Specifically, eight of these lesions received SABR treat-ment with a radiation dose of 50 Gy. Results: The therapy resulted in partial response after six months. The patient attained a progression-free survival period of 24 months. This case marks the first documented instance of effective application of triple-combination therapy in treating EC. Con-clusion: We opine that this therapy holds great promise as a second-line treatment for EC patients who have developed lung metastases. Notwithstanding the promising results, further exploration of this treatment avenue is warranted.
文章引用：刘昕, 王天昶, 穆允凤, 刘鹏, 王锋刚, 刘秋芳. 1例三联治疗难治性子宫内膜癌多发肺转移病案报道及文献复习[J]. 临床医学进展, 2023, 13(7): 11340-11347. https://doi.org/10.12677/ACM.2023.1371585

参考文献

[1] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clini-cians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[2] Concin, N., Matias-Guiu, X., Vergote, I., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. International Journal of Gynecologic Cancer, 31, 12-39. [Google Scholar] [CrossRef] [PubMed]
[3] Legge, F., Restaino, S., Leone, L., et al. (2020) Clinical Outcome of Recurrent Endometrial Cancer: Analysis of Post- Relapse Survival by Pattern of Recurrence and Secondary Treatment. International Journal of Gynecologic Cancer, 30, 193-200. [Google Scholar] [CrossRef] [PubMed]
[4] Kurra, V., Krajewski, K.M., Jagannathan, J., et al. (2013) Typical and Atypical Metastatic Sites of Recurrent Endometrial Car-cinoma. Cancer Imaging, 13, 113-122. [Google Scholar] [CrossRef] [PubMed]
[5] Fader, A.N., Roque, D.M., Siegel, E., et al. (2018) Randomized Phase II Trial of Carboplatin-Paclitaxel versus Car-boplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Re-ceptor 2/Neu. Journal of Clinical Oncology, 36, 2044-2051. [Google Scholar] [CrossRef] 
[6] Herrera, F.G., Bourhis, J. and Coukos, G. (2017) Radiotherapy Combination Opportunities Leveraging Immunity for the Next Oncology Practice. CA: A Cancer Journal for Clinicians, 67, 65-85. [Google Scholar] [CrossRef] [PubMed]
[7] Brooks, E.D. and Chang, J.Y. (2019) Time to Abandon Sin-gle-Site Irradiation for Inducing Abscopal Effects. Nature Reviews Clinical Oncology, 16, 123-135. [Google Scholar] [CrossRef] [PubMed]
[8] Zhao, X., Kong, Y. and Zhang, L. (2020) Anti-PD-1 Immuno-therapy Combined with Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Pa-tient with Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncology, 10, Article 1625. [Google Scholar] [CrossRef] [PubMed]
[9] He, H., Xu, T., Li, P., et al. (2021) Anti-PD-1 Immunotherapy Com-bined with Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient with Re-fractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncology, 11, Article 782646. [Google Scholar] [CrossRef] [PubMed]
[10] Xu, H., Hong, Z., Xu, M., et al. (2022) PRaG Therapy of Refrac-tory Metastatic Gastric Cancer: A Case Report. Frontiers in Immunology, 13, Article 926740. [Google Scholar] [CrossRef] [PubMed]
[11] Kong, Y., Zhao, X., Xu, M., et al. (2022) PD-1 Inhibitor Com-bined with Radiotherapy and GM-CSF (PRaG) in Patients with Metastatic Solid Tumors: An Open-Label Phase II Study. Frontiers in Immunology, 13, Article 952066. [Google Scholar] [CrossRef] [PubMed]
[12] Lin, Q., Sun, X., Zhou, N., et al. (2019) Outcomes of Stereotactic Body Radiotherapy Versus Lobectomy for Stage I Non-Small Cell Lung Cancer: A Propensity Score Matching Analysis. BMC Pulmonary Medicine, 19, Article No. 98. [Google Scholar] [CrossRef] [PubMed]
[13] Kimura, T., Fujiwara, T., Kameoka, T., Adachi, Y. and Kariya, S. (2022) Stereotactic Body Radiation Therapy for Metastatic Lung Metastases. Japanese Journal of Radiology, 40, 995-1005. [Google Scholar] [CrossRef] [PubMed]
[14] Palma, D.A., Olson, R., Harrow, S., et al. (2020) Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 38, 2830-2838. [Google Scholar] [CrossRef] 
[15] Nakamura, R., Sugawara, J., Yamaguchi, S., et al. (2020) Stereotactic Body Radiotherapy with a Single Isocentre for Multiple Pulmonary Metastases. BJR|Case Reports, 6, Article ID: 20190121. [Google Scholar] [CrossRef] [PubMed]
[16] Feng, L., Ye, T., Zhang, J., et al. (2022) Stereotactic Body Radiotherapy for Lung Metastases in a Patient with Giant Cell Tumor of Bone: A Case Report and Literature Review. Annals of Translational Medicine, 10, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
[17] Oaknin, A., Gilbert, L., Tinker, A.V., et al. (2022) Safety and Anti-tumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/ Stable (MMRp/MSS) Endometrial Cancer: Interim Results from GARNET—A Phase I, Single-Arm Study. Journal for Immunotherapy of Cancer, 10, e3777. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, D., et al. (2022) Phase 2 Study of Tislelizumab Monotherapy in Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-High/Mismatch Re-pair-Deficient Solid Tumors: Gynecological Cancer Subgroup (127). Journal of Gvnecoloaic Oncoloay, 166, S80-S81. [Google Scholar] [CrossRef] 
[19] Makker, V., Rasco, D., Vogelzang, N.J., et al. (2019) Len-vatinib plus Pembrolizumab in Patients with Advanced Endometrial Cancer: An Interim Analysis of a Multicentre, Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 20, 711-718. [Google Scholar] [CrossRef] 
[20] Yonemori, K., Yunokawa, M., Ushijima, K., et al. (2022) Lenvatinib plus Pembrolizumab in Japanese Patients with Endometrial Cancer: Results from Study 309/KEYNOT-775. Cancer Science, 113, 3489-3497. [Google Scholar] [CrossRef] [PubMed]
[21] Konstantinopoulos, P.A., Gockley, A.A., Xiong, N., et al. (2022) Evalua-tion of Treatment with Talazoparib and Avelumab in Patients with Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncology, 8, 1317-1322. [Google Scholar] [CrossRef] [PubMed]
[22] Ni, J., Zhou, Y., Wu, L., et al. (2021) Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-Arm, Phase II Trial. Radiation Oncology, 16, Article No. 177. [Google Scholar] [CrossRef] [PubMed]
[23] Jiao, Y., Cao, F. and Liu, H. (2022) Radiation-Induced Cell Death and Its Mechanisms. Health Physics, 123, 376-386. [Google Scholar] [CrossRef] 
[24] Kong, Y., Ma, Y., Zhao, X., et al. (2021) Optimizing the Treatment Schedule of Radiotherapy Combined with Anti- PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Frontiers in Oncology, 11, Article 638873. [Google Scholar] [CrossRef] [PubMed]
[25] Bernstein, M.B., Krishnan, S., Hodge, J.W. and Chang, J.Y. (2016) Immunotherapy and Stereotactic Ablative Radio- therapy (ISABR): A Curative Approach? Nature Reviews Clinical On-cology, 13, 516-524. [Google Scholar] [CrossRef] [PubMed]
[26] Breen, W.G., Leventakos, K., Dong, H. and Merrell, K.W. (2020) Radiation and Immunotherapy: Emerging Mechanisms of Synergy. Journal of Thoracic Disease, 12, 7011-7023. [Google Scholar] [CrossRef] [PubMed]
[27] Popp, I., Grosu, A.L., Niedermann, G. and Duda, D.G. (2016) Immune Modulation by Hypofractionated Stereotactic Radiation Therapy: Therapeutic Implications. Radiotherapy and Oncology, 120, 185-194. [Google Scholar] [CrossRef] [PubMed]
[28] Golden, E.B., Marciscano, A.E. and Formenti, S.C. (2020) Ra-diation Therapy and the in Situ Vaccination Approach. International Journal of Radiation Oncology, Biology, Physics, 108, 891-898. [Google Scholar] [CrossRef] [PubMed]
[29] Turgeon, G.-A., Weickhardt, A., Azad, A.A., Solomon, B. and Siva, S. (2019) Radiotherapy and Immunotherapy: A Synergistic Effect in Cancer Care. Medical Journal of Australia, 210, 47-53. [Google Scholar] [CrossRef] [PubMed]
[30] Mayoux, M., Roller, A., Pulko, V., et al. (2020) Dendritic Cells Dictate Responses to PD-L1 Blockade Cancer Immunotherapy. Science Translational Medicine, 12, eaav7431. [Google Scholar] [CrossRef] [PubMed]
[31] Lee, A. and Keam, S.J. (2020) Tislelizumab: First Approval. Drugs, 80, 617-624. [Google Scholar] [CrossRef] [PubMed]
[32] Kwek, S.S., Kahn, J., Greaney, S.K., et al. (2016) GM-CSF and Ipilimumab Therapy in Metastatic Melanoma: Clinical Outcomes and Immunologic Responses. OncoImmunology, 5, e1101204. [Google Scholar] [CrossRef] 
[33] Liu, M., Cai, X. and Zeng, Y. (2019) EP1.04-28 The Ab-scopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers. Journal of Thoracic Oncology, 14, S980. [Google Scholar] [CrossRef] 
[34] Chen, Y., Gao, M., Huang, Z., Yu, J. and Meng, X. (2020) SBRT Combined with PD-1/PD-L1 Inhibitors in NSCLC Treatment: A Focus on the Mechanisms, Advances, and Future Chal-lenges. Journal of Hematology & Oncology, 13, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[35] Bezjak, A., Paulus, R., Gaspar, L.E., et al. (2019) Safety and Ef-ficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. Journal of Clinical Oncology, 37, 1316-1325. [Google Scholar] [CrossRef] 
[36] Kong, F.S., Moiseenko, V., Zhao, J., et al. (2021) Organs at Risk Con-siderations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? International Journal of Radiation Oncology, Biology, Physics, 110, 172-187. [Google Scholar] [CrossRef] [PubMed]

为你推荐